Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：24
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [21] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [22] Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer
    James E. Frampton
    BioDrugs, 2015, 29 : 143 - 150
  • [23] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    Ledermann, Jonathan
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Macpherson, Euan
    Watkins, Claire
    Carmichael, James
    Matulonis, Ursula
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15): : 1382 - 1392
  • [24] Cutaneous arteritis during olaparib treatment for ovarian cancer
    Iinuma, Shin
    Takahashi, Chiaki
    Negishi, Hideaki
    Ishida-Yamamoto, Akemi
    JOURNAL OF DERMATOLOGY, 2021, 48 (03): : E140 - E141
  • [25] Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Julia Paik
    Targeted Oncology, 2021, 16 : 847 - 856
  • [26] Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Paik, Julia
    TARGETED ONCOLOGY, 2021, 16 (06) : 847 - 856
  • [27] Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
    Wu, Lei
    Zhong, Lixian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 187 - 195
  • [28] Olaparib maintenance for first-line treatment of ovarian cancer:will SOLO1 reset the standard of care?
    Miller, Rowan E.
    Crusz, Shanthini M.
    Ledermann, Jonathan A.
    FUTURE ONCOLOGY, 2019, 15 (16) : 1845 - 1853
  • [29] An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer
    Wolford, J. E.
    Liang, S. Y.
    Tewari, K. S.
    Eskander, R. N.
    Kapp, D. S.
    Mann, A. K.
    Chan, J. K.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 25 - 25
  • [30] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
12345